Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial

被引：0
|
作者：
Smeenk, M. M. [1 ]
van Diessen, J. N. A. [1 ]
Boellaard, T. N. [1 ]
Hartemink, K. J. [1 ]
de Vries, J. F. [1 ]
Badrising, S. K. [1 ]
Wondergem, M. [1 ]
Wittenberg, R. [1 ]
Monkhorst, K. [1 ]
van den Heuvel, M. M. [2 ]
Theelen, W. S. M. E. [1 ]
机构：
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Induction; Immunotherapy; Locally advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA16.03
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Mehra, Ranee
    Yong, Candice
    Seal, Brian
    van Keep, Marjolijn
    Raad, Angie
    Zhang, Yiduo
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (02): : 153 - +
  • [32] Durvalumab plus tremelimumab in biologically selected advanced/metastatic solid tumors
    De la Fouchardiere, Christelle
    Gomez-Roca, Carlos A.
    De Montfort, Aymeric
    Italiano, Antoine
    Gilabert, Marine
    Tredan, Olivier
    Korakis, Iphig Nie
    Ray-Coquard, Isabelle Laure
    Rochefort, Pauline
    Dufresne, Armelle
    Cousin, Sophie
    Le Tourneau, Christophe
    You, Benoit
    Bertucci, Francois
    Cassier, Philippe Alexandre
    Attignon, Vale Prime Ry
    Mayet, Romaine
    Garin, Gwenaelle
    Perol, David
    Blay, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
    Vansteenkiste, Johan F.
    Naidoo, Jarushka
    Faivre-Finn, Corinne
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Murakami, Shuji
    Hui, Rina
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Kubota, Kaoru
    Broadhurst, Helen
    Wadsworth, Catherine
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [34] Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
    Garassino, Marina C.
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Bischoff, Helge
    Reinmuth, Niels
    Cove-Smith, Laura
    Mansy, Talal
    Cortinovis, Diego
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (12) : 1415 - 1427
  • [35] Induction chemotherapy and concomitant chemoradiotherapy (CRT) in patients with unresectable, locally advanced pancreatic carcinoma
    Kurt, M
    Kurt, E
    Cetintas, SK
    Evrensel, T
    Manavoglu, O
    Engin, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 354S - 354S
  • [36] The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
    Takada, Ryoji
    Ikezawa, Kenji
    Daiku, Kazuma
    Maeda, Shingo
    Abe, Yutaro
    Urabe, Makiko
    Kai, Yugo
    Yamai, Takuo
    Fukutake, Nobuyasu
    Nakabori, Tasuku
    Uehara, Hiroyuki
    Ashida, Reiko
    Akita, Hirofumi
    Takahashi, Hidenori
    Teshima, Teruki
    Ohkawa, Kazuyoshi
    CANCERS, 2021, 13 (18)
  • [37] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial (vol 21, pg 1574, 2020)
    Powles, T.
    van der Heijden, M. S.
    Castellano, D.
    LANCET ONCOLOGY, 2021, 22 (01): : E5 - E5
  • [38] Impact of induction chemotherapy prior to chemoradiotherapy on survival in patients with locally advanced non-small cell lung cancer (NSCLC)
    Ozkan, A.
    Kocak, M.
    Mayadagli, A.
    Parlak, C.
    Demir, O.
    Marti, A.
    Yilmaz, A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S389 - S390
  • [39] Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC
    Hui, R.
    Ozguroglu, M.
    Daniel, D.
    Baz, D.
    Murakami, S.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    De Wit, M.
    Cho, B. Chul
    Gray, J.
    Ryden, A.
    Viviers, L.
    Poole, L.
    Dennis, P.
    Antonia, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1604 - S1604
  • [40] Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab
    Unome, Shinji
    Imai, Kenji
    Miwa, Takao
    Hanai, Tatsunori
    Suetsugu, Atsushi
    Takai, Koji
    Suzui, Natsuko
    Miyazaki, Tatsuhiko
    Shimizu, Masahito
    INTERNAL MEDICINE, 2024, 63 (19) : 2631 - 2636
12345